Innate Pharma Provides Q2 2026 Business Update and Financial Results
Innate Pharma (IPHA) held its first half of 2026 business update and financial results call on September 17, 2026. The company highlighted key developments across its portfolio, including the initiation of a Phase 3 trial for lacutamab in T-cell lymphoma following a partnership with Sobe. Innate Pharma also reported progress in trials involving IPH4500 and monalizumab, noting preliminary antitumor activity observed in several cancers. Financially, the company received an upfront payment of €75 million from its deal with Sobe and raised €30 million through equity financing. These funds are expected to extend Innate Pharma’s cash runway until early 2028. The CEO emphasized that these developments position the company for several important catalysts in the second half of 2026, including data readouts from ongoing trials. The call included presentations by senior executives covering strategic updates and financial performance, followed by a Q&A session with investors.
